Introduction The objectives of this study were to estimate the economic burden of HPV in Italy, accounting for total direct medical costs associated with nine major HPV-related diseases, and to provide a measure of the burden attributable to HPV 6, 11, 16, 18, 31, 33, 45, 52, 58 infections. Methods A cost-of-illness incidence-based model was developed to estimate the incidences and costs of invasive cervical cancer, cervical dysplasia, cancer of the vulva, vagina, anus, penis, oropharyngeal, anogenital warts, and recurrent respiratory papillomatosis (RRP) in the context of the Italian National Health System (NHS). We used data from hospital discharge records (HDRs) of an Italian region and conducted a systematic literature review to estimate the lifetime cost per case, the number of incident cases, the prevalence of HPV9 types. Costs of therapeutic options not included in the diagnosis-related group (DRG) tariffs were estimated through a scenario analysis. Results In 2018, the total annual direct costs were €542.7 million, with a range of €346.7-€782.0 million. These costs could increase considering innovative therapies for cancer treatment (range €16.2-€37.5 million). The fraction attributable to the HPV9 genotypes without innovative cancers treatment was €329.5 million, accounting for 61% of the total annual burden of HPV-related diseases in Italy. Of this amount, €135.9 million (41%) was related to men, accounting for 64% of the costs associated with non-cervical conditions. Conclusions The infections by HPV9 strains and the economic burden of non-cervical HPV-related diseases in men were found to be the main drivers of direct costs.
Introduction
Human papillomavirus (HPV) is the most common sexually transmitted virus and causes a substantial burden of disease in both men and women [1] . The prevalence of HPV remains unacceptably high. In 2013-2014, approximately 45% of men and 40% of women between the ages of 18 and 59 had genital HPV infection [2] . Genital HPV infections are contracted through unprotected vaginal or anal sexual intercourse and skin-to-skin genital contact. HPV infections that result in oral or upper respiratory malignancies are mostly contracted through unprotected oral sex [3] . Most HPV infections are asymptomatic and resolve within a few months of exposure. However, the infection can progress to form pre-cancerous and cancerous lesions. HPV has been shown to be the cause of several clinically significant conditions. As of this writing, more than 100 types of papillomavirus strains that can infect humans have been identified. These have been divided into high-and low-risk types according to their risk of progressing to cancer. The high-risk oncogenic variants of HPV, specifically genotypes 16 and 18, account for approximately 70% of all cases of invasive cervical cancer and cervical dysplasia worldwide [4, 5] . They also account for a smaller fraction of cancers of the vulva, vagina, anus, penis, head and neck [6] . The low-risk HPV variants of genotypes 6 and 11 are responsible for approximately 90% of benign external anogenital warts [7] and almost all cases of recurrent respiratory papillomatosis (RRP) [8, 9] .
Primary prevention of HPV-related diseases is possible with vaccination. Three vaccines (Cervarix, Gardasil and Gardasil9) are currently approved for the prevention of HPV infection. All of these vaccines are active against the highrisk HPV 16 and 18 strains, while Gardasil® also protects against HPV 6 and 11. Gardasil9 was authorized in the European market in 2015 and protects against nine strains of HPV, including types 6, 11, 16, 18, 31, 33, 45, 52 , and 58 [10, 11] . The availability of these vaccines has led to the initiation of population-wide immunization programmes in most western countries. Based on previous cost-effectiveness studies, the primary aim of most HPV immunization programmes has been to protect women against cervical cancer [12] [13] [14] . However, a study published in 2012 demonstrated the relevance of the burden of HPV malignancies in men to all who pay for healthcare services (the Italian National Health System, NHS) [15] . A subsequent study demonstrated the cost-effectiveness of gender-neutral immunization in Italy [14] . Based on these findings, in 2017, the Italian Government became the first of the G9 countries to introduce a universal, recommended and free vaccination for HPV for girls and boys at the age of 12 [16] .
Because of these policy changes, the aim of the study was to provide an estimate of the total, direct medical costs attributable to HPV infection, with stratification of the burden by sex as well as specific diseases using cost inputs taken from the Italian National Health Service. Furthermore, this study also calculated an aggregate measure of the total economic burden attributable to HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58 infections as an estimate of the potential savings due to the introduction of the nine-valent universal HPV vaccination programme.
Methods

Study design
The study design was developed using the Italian National Health Service (NHS), from which the cost inputs were selected. A systematic review of the literature was conducted to identify economic and epidemiological data related to each HPV-induced disease. The review was aimed to identify the best secondary data available to produce lifetime costs per case estimates. In particular we searched for epidemiological data such as incidence and prevalence rates as well as direct cost estimates from the perspective of the Italian national payer. As a result, lifetime costs for cervical dysplasia, anogenital warts and cervical cancer were modelled based on a number of previously published studies (Table 1 ) [17] . Due to the lack of available information regarding RRP in the Italian context, treatment assumptions were speculated for this disease on the basis of international literature as well as tariffs applied by Italian diagnosis-related groups (DRGs).
Real-world data were used to estimate hospital-based management costs of the main HPV-induced malignancies: cervical, vulvar, vaginal, penile, head and neck cancer. Specifically, hospital discharge records (HDRs) from 2010 to 2014 from the administrative archives of the Marche region were analysed to identify hospitalization rates as well as the costs associated with HPV-related diseases. This approach was followed and validated by previous publications made in this field [24] . Finally, outpatient costs related to these malignancies were estimated based on the latest national tariffs (2013) for specialist consultation procedures, and treatment paradigms were validated by the expert opinions of a group of clinicians. An incidence-based approach was then adopted to estimate lifetime costs per case and produce an aggregate measure of the economic burden. The relative prevalence rates of HPV types 6, 11, 16, 18, 31, 33, 45, 52 , and 58 according to the literature were applied to estimate the aggregate fraction of costs attributable to HPV infections in Italy.
Real-world data analysis
Information related to the hospital discharges (HDRs) of all accredited public and private hospitals in the Marche Region, both for ordinary and day-care regimens, were included to estimate the costs of cervical, vulvar, vaginal, penile, head and neck cancer. The total costs related to hospitalizations were calculated using the DRGs (with 2013 values) of hospitalized patients based on their age, gender and their consumption of resources during their hospital stay. The DRG system aggregates all activities, including surgical interventions, administered drugs, expended materials and personnel for each individual diagnosis and stipulates the reimbursement tariff. This value corresponds to the total amount of all interventions provided that is to be paid to the hospital. According to the DRG-based reimbursement system, every hospitalized patient was assigned to a group of diagnostically homogeneous cases; therefore, patients with the same DRG values were assigned the same reimbursement charges.
We included hospitalizations of patients who were residents of the Marche region, were older than 18 years of pathway followed by [21] which was validated here by the clinical experts involved in the study. In particular based on the clinical guidelines and current practices, a number of procedures per each diagnose was established to represent the amount of outpatient services provided to patients lifetime. Outpatient costs were then applied based on the 2013 national tariffs for specialists' office consultations and procedures [15] .
Literature review
Secondary data were identified through a systematic literature review. The search was carried out according to the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines [25] (Fig. 1) 
Screening and data extraction
Two independent researchers screened the titles and abstracts. Full-text articles were included if they met the following inclusion criteria: (1) they reported epidemiological data (incident cases by disease and the prevalence of HPV by genotype) derived from population databases, such as national surveys or registries; and (2) they reported direct cost data from the perspective of the payer and expressed monetary values for hospital DRGs and outpatient tariffs. Studies were also required to contain estimates of reported lifetime costs or appropriate data to estimate these costs. For all phases of the literature review, disagreements were resolved by discussions among the entire team to reach a consensus.
Lifetime costs
An incidence-based approach was adopted in which the lifetime costs per case associated with each condition were applied to the estimated number of incident cases that were attributable to HPV. We sought to develop cost-per-case estimates that represented the current values of the total direct medical costs accrued from the time of diagnosis to the end of follow-up (Table 1) . Specifically, cost estimates for cervical cancer were obtained from a published Italian study [17] that estimated the mean total direct costs for cervical cancer, including those generated by the management of disease progression and recurrence. The actual costs were not reported, although the median follow-up duration of the cohort was 23 months (range 1-89). We assumed that the mean cost per patient for primary tumour treatment (€13,122) was incurred within year 1, whereas the mean cost associated with the management of disease progression and recurrence (€9092) was incurred in the following year, and we reduced this secondyear value by 3% (€8827). The selected discount rate (3%) reflects the opportunity costs of financing from the perspective of a public payer (the Italian NHS) according to Italian AIES (Italian Health Economics Association) guidelines [26] .
Lifetime costs associated with the clinical and surgical management of cervical dysplasia were estimated from published Italian data [18, 19] .
The lifetime cost per patient of non-cervical malignancies was modelled on the national treatment guidelines of a previously published study [15] . Therefore, in addition to the real-world data used to estimate the lifetime costs of hospitalization, we also included two clinical examinations conducted by specialists and two two-sector computed tomography (CT) scans per year. These costs were then reported over a 3-year follow-up period, which is consistent with the realworld data according to [15] and expert opinion. Outpatient fees were attributed to each surgical procedure and medical treatment using national outpatient tariff values (2013). Hospitalization costs (including outpatient costs) incurred after the first 12 months of treatment were discounted at a rate of 3% per year to obtain their current net value expressed in the value of the Euro in 2013.
The estimated lifetime cost of anogenital warts per incident case was calculated as the sum of the mean, inflationadjusted direct costs incurred by new patients (€416 for women and €311 for men) and the probable, discounted, inflation-adjusted mean direct costs of recurrent (€199 for women and €66 for men) and resistant (€48 for women and €92 for men) episodes observed over 1 year after initial diagnosis. These figures were modelled on a previously published article [22] . Probability rates were calculated based on the number of recurrent (50.6% for women and 34.8% for men) and resistant (28.2% for women and 38.5% for men) cases reported as a percentage of the annual number of newly diagnosed cases, assuming a steady state in the total number of genital warts treated in Italy [22] .
Finally, to estimate the lifetime cost per RRP patient, elective surgical procedures and medical treatments were selected according to published reports from the US [27, 28] . Treatment assumptions included the management of complicated respiratory infections, three acute clinical treatments, 4.4 surgical procedures, and a tracheotomy rate of 11% per year [27] . Italian DRG tariffs for 2013 were applied to the selected procedures. The duration of the disease was estimated to be 4.2 years [27] . All costs incurred after the first 12 months of treatment were discounted at a rate of 3% per year to obtain their current net value expressed in the value of the Euro in 2013.
All costs related to each HPV-induced disease included in the study (Table 1) were adjusted for inflation in 2018 using the compound annual Italian National Consumer Price Indexes (NIC) provided by the Italian National Institute of Statistics (ISTAT).
Incidence and HPV9 genotype attribution
An estimate of the incident cases in the population over 18 years of age in Italy in 2018 [29] was obtained from the systematic literature review using the mean of the ranges provided by the selected studies. Crude incident rates per 100,000 residents in the 2018 resident Italian population [29] were calculated ( Table 2 ). Due to the heterogeneity of the rates reviewed and the number of diseases involved, no standardization, meta-analyses or adjustments for the pyramidal stratification of the observed population were attempted. Due to a lack of Italian epidemiological data, the incidence of RPP was deliberately selected from the lower limit of the range cited in the literature [15] .
Moreover, to estimate the costs attributable to HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58, prevalence rates of HPV DNA and genotype attribution per condition were identified from the systematic review. Specifically, for each condition, we first calculated the percentage of DNA attribution to exclude all cases that were not a result of HPV infection. We then applied prevalence rates from the literature to calculate the individual fractions attributable to genotypes included in HPV9 vaccine (Table 3 and Annexe A). These values were used to calculate the fraction of the total economic burden of HPV-induced malignancies attributable to the nine genotypes by both disease and sex according to the number of estimated incident cases.
Statistical analyses
Probabilistic and Deterministic Sensitivity Analyses (PSA and DSA) were developed to account for the variability of data used in the model. The PSA employed the differences found in the examined sources indicating minimum and maximum values of the uncertainty distribution for each parameter. The probabilistic distribution was prepared by applying normally reported values for the development of probabilistic models in economic evaluations, distinguishing between costs (gamma distribution) and epidemiological parameters (beta distribution) [41] . The distribution of each parameter was then used to perform 5000 Monte Carlo simulations to obtain interval estimates (95% confidence interval (CI)) for the main epidemiological and economic data (Annex C).
The DSA was performed by adjusting each parameter to the highest and lowest possible values of the data obtained from the systematic review with a one-way approach. When a plausible range was not available from the literature, we assumed a variation of 10%.
The critical parameters used to assess the uncertainty were: the number of incident cases per year, the HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58, genotype attributions and cost parameters. We measured the impact of inserting the highest and lowest values for: (1) all diseases, (2) only oncologic diseases (defined as the sum of cervical, anal, oropharyngeal, vulvar, vaginal and penile cancers) (3) non-oncologic (cervical dysplasia, anogenital warts and RRP).
Cost estimates of innovative therapeutic options not included in the DRG tariffs
The DRG tariffs used as the main inputs for evaluating the direct costs of hospitalization did not include the costs of innovative therapeutic options that were added to the treatment guidelines for HPV-induced malignancies after 2013. The costs of these new drugs were actually debited to a National Account (named "File F"), which was specifically created to account for highly innovative therapeutic options. However, the administrative costs were paid for by the DRG tariff. File F is not accessible and does not provide information on the use of innovative drugs by indication. Therefore, identifying the resources allocated from File F used to treat HPV-induced malignancies is impossible. Ignoring these costs, however, would significantly underestimate the burden of HPV-induced diseases carried by the NHS. Therefore, we used the scenario analysis [42] method to estimate a range of credible costs for the innovative therapies used to treat HPV-induced malignancies. Following the latest guidelines of the Associazione Italiana di Oncologia Medica (AIOM) for the treatment of HPV-induced malignancies, two innovative therapeutic options were identified:
• Cetuximab (Erbitux), indicated for the treatment of head and neck cancer; • Bevacizumab (Avastin), indicated for the treatment of recurrent or refractory cervical cancer.
The treatment and cost inputs used to determine the three scenarios are reported in Annex A.
Results
The annual incidence of the nine HPV-related conditions corresponded to approximately 1.1 million cases of which 975,000 associated to cervical conditions (86%), and 158,000 to non-cervical (14%). In 2018, the total direct [38] [39] [40] costs (expressed relative to the 2018 Euro) associated with the annual incident cases of cervical cancer, cervical dysplasia, vulvar, vaginal, anus, penis and head and neck cancers, anogenital warts, and RRP in Italy were estimated to be €542.7 million, with a credible range of €346.7-€782.0 million. These costs could increase considering also the impact of innovative therapies for cancers treatment included in the scenario analysis with a plausible range between €16.2 and €37.5 million. The fraction attributable to the nine HPV9 genotypes included in our base case analysis, without considering the impact of innovative therapies, was €329.5 million (range €157.0-€564.9 million), accounting for approximately 61% of the total annual burden of HPV-related diseases in Italy.
Cervical conditions
The total cost estimate for cervical conditions was €149.9 million (range €132.0-€168.9 million), which corresponds to 28% of the total economic burden associated with HPV-related diseases in Italy, (Table 3) . Of this amount, €69.7 (range €59.1-€81.2 million) and €80.2 million (range €66.2-€95.6 million) were due to cervical cancer and total cervical dysplasia, respectively-estimates that include diagnosis, colposcopies, PAP smears and cervical neoplasia (CIN1/2/3). Additionally, the total annual cost associated with the management of cervical lesions, including the diagnosis and treatment of CIN1/2/3 stages, was €54.0 million (range €41.0-€68.7 million). The fraction of cervical conditions attributable to HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was estimated to be €118.3 million (range €104.2-€133.3 million), 53% of which was related to cervical cancers (€62.3 million, range €52.6-€72.8).
Non-cervical malignancies
We evaluated the direct costs related to the treatment and follow-up of HPV-related cases of seven non-cervical CIN cervical intra-epithelial neoplasia, RRP recurrent respiratory papillomatosis malignancies: cancer of the anus, oropharynx, vulva, vagina, and penis, anogenital warts and RPP. The economic burden associated with non-cervical conditions was €392.9 million, with a range of €206.3-€638.4 million. The amount corresponds to 72% of the total costs associated with HPV-related diseases in Italy. Oropharyngeal cancers were responsible for the highest annual burden of direct costs (€215.7 million, €187.0 for men and €28.7 for women), followed by anogenital warts (€85.9 million, €41.2 for men and €44.6 for women) and RPP (€53.6 million). The costs related to all HPV-related diseases included in our study are reported in Table 3 . According to our systematic review, HPV virus were responsible for 36.6% of vulvar and vaginal cancers and 40% of oropharyngeal cancers, respectively, as well as 88% and 50% [30] of anal and penile cancers, respectively. The estimated fractions of the total annual direct costs attributable to HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58-induced non-cervical malignancies were €211.2 million (range €58.5-€460.1 million), 61% of which was attributable to HPV 6 and 11. Table 4 reports the outcomes of the scenario analysis. Three scenarios were obtained by varying the potential number of patients treated and the future availability of similar treatments at a reduced price. The credible range of the incremental costs allocated to innovative treatments of HPV-induced malignancies was €16.2-€37.5 million. This range represents a significant incremental cost compared to the DRG tariffs for the HPV-induced malignancies, ranging from 12.8 to 29.8%.
Cost of innovative therapies not included in DRG tariffs
The availability of similar therapies would reduce the incremental cost by approximately 22%.
The fraction of HPV9-genotype costs attributable to men was equal to €137.7, while women accounted for €194.4. This corresponded to 58% of total costs attributable to HPV9 infections for women, whereas men accounted for 42%. On the other hand, the economic burden of HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58 infections that were related to noncervical conditions was higher for men than women (64.4% vs 35.6% of the total, respectively) (Fig. 2) .
The Tornado chart shown in Fig. 3 shows that the uncertainty in our evaluation of the economic burden of HPV9-related diseases is mostly associated with the range of possible incidence rates for all groups of disease and costs.
Discussion
The purpose of this analysis was to estimate the economic burden of HPV-related diseases in Italy. Our study attempted to measure the direct costs from the real-world data perspective of the Italian National Health Service. The authors adopted a real-world data approach to estimate lifetime costs and conducted a systematic literature review to construct our estimation models with the most recent data available. Additionally, we included the nine HPV genotypes included in the new nine-valent vaccine that was made available in Europe in the last 2 years. Therefore, the present study is a first attempt to measure the economic burden of HPV-related diseases in Italy considering the newly available vaccine and data. By estimating the resource consumption attributable to the nine genotypes, we aim to predict the effects of both the 2017-2019 National Immunization Plan and the strategies recently adopted in Italy and to inform future public health decisions.
According to the results of this study, costs related to CIN1 treatment, vaginal cancer and cervical cancer were the most heavily influenced when including five HPV genotypes that accounted for 28% of their total cost on average. Furthermore, the economic burden among men represented more than one-third (42%) of the total direct costs of HPV9 genotype-related diseases, including cervical conditions, which is consistent with previously published data [6, 15] and with the effort to extend the anti-HPV immunization programme to include boys in the National Immunization Plan 2017-2019.
The present study has several limitations. First, real-world data from administrative archives were only available for anal, head and neck, vulvar, vaginal and penile cancers, and published Italian sources of cost data were limited. Additionally, the quality of the available information was variable. Therefore, the use of different data sources may have diminished the comprehensiveness of our data. Specifically, the use of administrative data required certain assumptions to consistently estimate the lifetime costs from different data sources. Hospital discharge forms may have codification problems; therefore some information may be missing and/ or be wrongly reported. In this case, our analysis may have missed this information (due to the inclusion criteria), with the risk of underestimating the economic and epidemiological burden of the considered HPV-related diseases. Additionally, not all diseases led to hospitalization and this may be a further source of underestimation. Additionally, due to the scarcity of available data, we did not include drug utilization in our estimates. These limitations should be considered in future research; however, in our opinion, they do not undermine the validity of the cost estimates in the present study or their estimated impact on the total economic burden of HPV-related diseases. Future research should address these gaps in epidemiological and cost data to reduce the uncertainty associated with the present estimates. In conclusion, the present analysis is the first to provide a snapshot of the current state of resource utilization in Italy and the expected economic effects resulting from the 2017-2019 National Immunization Plan. Therefore, we believe that this analysis may provide a tool for keeping records of the expected economic effects over time.
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